FDA clears line of Sorin pacemakers

08/7/2008 | FDAnews

Sorin Group has received FDA approval to market its Reply family of single- and dual-chamber pacemakers. The devices are designed for use in patients with sinus node disease and atrioventricular block to decrease unnecessary pacing, which can cause heart failure and atrial fibrillation.

View Full Article in:

FDAnews

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Paralegal, Legal-Regulatory
Confidential
Piscataway, NJ